AstraZeneca PLC (LON:AZN) Given Consensus Rating of “Moderate Buy” by Brokerages

AstraZeneca PLC (LON:AZN) has been assigned a consensus rating of “Moderate Buy” from the six brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is £153.33.

Several research analysts have weighed in on AZN shares. Citigroup boosted their price target on AstraZeneca from £170 to £180 and gave the company a “buy” rating in a report on Friday, April 10th. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating and issued a £115 price target on shares of AstraZeneca in a report on Tuesday. Finally, Jefferies Financial Group restated a “buy” rating and set a £180 price objective on shares of AstraZeneca in a report on Wednesday, May 13th.

AstraZeneca Price Performance

AZN stock opened at £138.58 on Monday. The company has a current ratio of 0.91, a quick ratio of 0.59 and a debt-to-equity ratio of 71.66. The company has a market cap of £214.92 billion, a price-to-earnings ratio of 20.87, a PEG ratio of 0.86 and a beta of 0.22. The firm has a 50 day moving average of £141.97 and a 200-day moving average of £141.36. AstraZeneca has a 12-month low of £101.03 and a 12-month high of £157.32.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.